23.01
23.01 (0.00%)
As of Jan 19, 2021
Viridian Therapeutics, Inc. [MGEN]
Source:
Company Overview
Viridian Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target disease areas where marketed therapies often leave room for improvements in efficacy, safety, and/or dosing convenience.
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | 617.272.4600 |
| Industry | services |
| CEO | Stephen Mahoney |
| Website | www.viridiantherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.3 |
| Operating Profit | $-299 |
| Net Income | $-269.9 |
| Net Cash | $-3.2 |
Profit Ratios
| Gross Margin | $0.3 |
| Operating Margin | -99,018.2 |
| Profit as % of Revenues | -0.1% |
| Profit as % of Assets | -43.8% |
| Profit as % of Stockholder Equity | -40.2% |
Management Effectiveness
| Return on Equity | -40.2% |
| Return on Assets | -36.4% |
| Turnover Ratio | 0.1% |
| EBITA | $-299 |
Balance Sheet and Cash Flow Measures
| Total Assets | $742.4 |
| Total Liabilities | $70.8 |
| Operating Cash Flow | $-232.3 |
| Investing Cash Flow | $-228.7 |
| Financing Cash Flow | $457.7 |
